Imagine bringing together the exact people you need to meet, senior decision makers from your target accounts, in an environment where real conversations happen naturally. No exhibition halls. No PowerPoint decks. Just exceptional food, thoughtful curation, and the kind of evening people remember.
Three industry verticals. One clearer view of where the market is moving.
Blockbuster revenue is under pressure. Lifecycle strategies are shifting towards reformulation and alternative delivery.
Repositioning delivers faster returns with significantly lower cost and risk than new discovery.
Formulation and device integration are becoming central to portfolio strategy.
Delivery systems are directly impacting efficacy, usability and regulatory outcomes.
The right device creates competitive advantage. The wrong one can derail development.
Complex biologics and advanced therapies are failing later due to formulation challenges.
Biotech companies are embedding formulation expertise earlier and partnering externally.
Expertise in lifecycle extension, asset repositioning, and formulation platform development across pharma portfolios.
Formulation science for NATs and AAV therapies. Deep investor perspective on Series A/B formulation strategy.
Combination product strategy and regulatory expertise. Led FDA/EMA submissions for drug-device combinations.
Scale-up and manufacturing strategy across complex delivery systems. Strong track record in supply chain resilience.
Leads integrated formulation + manufacturing + device platforms. Views convergence from CDMO perspective.
Tracks pharma-biotech-medtech convergence trends. Published research on integrated development models.
The life sciences industry moves fast. Cut through the noise and digest the strategic intelligence leaders need
to stay ahead. Analysis that contextualises what’s happening, why it matters and what comes next.
